NASDAQ : CNSY
Cerenome, Inc. — Key statistics
Healthcare · Medical - Pharmaceuticals · United States
Last price 1.74 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 13.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 12.90M |
| Enterprise Value | 4.36M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 7.59M |
| Shares Outstanding | 7.59M |
| Shares Change (YoY) | +830.64% |
| Shares Change (QoQ) | +3.80% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 14.42% |
| Float | 7.50M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.07 |
| Forward PS | 1.35 |
| PB Ratio | 2.27 |
| P/TBV Ratio | 2.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.37 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,200.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -614.05% |
| Return on Assets (ROA) | -135.36% |
| Return on Invested Capital (ROIC) | -385.02% |
| Return on Capital Employed (ROCE) | -483.25% |
| Weighted Average Cost of Capital (WACC) | 12.43% |
| Revenue Per Employee | $150,107 |
| Profits Per Employee | -$931,714 |
| Employee Count | 28 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -87.44% |
| 50-Day Moving Average | 2.12 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 43.19 |
| Average Volume (20 Days) | 83,417 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 782,146 |
| Short Previous Month | 749,056 |
| Short % of Shares Out | 10.31% |
| Short % of Float | 10.43% |
| Short Ratio (days to cover) | 4.54 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.20M |
| Gross Profit | -8.30M |
| Operating Income | -26.40M |
| Pretax Income | -26.09M |
| Net Income | -26.09M |
| EBITDA | -25.95M |
| EBIT | -26.40M |
| Loss Per Share | -$4.37 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.59M |
| Total Debt | 44,000 |
| Net Cash | 8.54M |
| Net Cash Per Share | $1.13 |
| Equity (Book Value) | 5.46M |
| Book Value Per Share | 0.75 |
| Working Capital | 3.20M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -22.18M |
| Capital Expenditures | -1.37M |
| Depreciation & Amortization | 455,000 |
| Net Borrowing | -22,000 |
| Free Cash Flow | -23.55M |
| FCF Per Share | -$3.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | -197.57% |
| Operating Margin | -628.12% |
| Pretax Margin | -620.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -830.64% |
| Shareholder Yield | -830.64% |
| Earnings Yield | -257.06% |
| FCF Yield | -182.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $27.75 |
| Price Target Difference | 1,532.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 105.61% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -55.16 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |